It’s been a few years since Brexit and pharmaceutical companies have been adapting their therapy development plans as regulatory guidelines for different regions get updated. Health technology assessments or HTAs remain one area where the divergence of reimbursement frameworks in the UK and European Union is expected to impact how and when new therapies become available in those regions.

In this month’s issue, we take a look at how market access following an evolving process to conduct HTAs is expected to change in the near future in the UK.

Also, in this issue, we tackle the sparse research landscape for treatments for prion diseases and whether all generic manufacturers can pivot to producing specialty and complex generics.

Do catch the guest columns on digital health in pharma, and how collaborative research has led to new ways to study long Covid.

All this, and the latest pharma industry news, comment, data, and analysis from GlobalData.

Manasi Vaidya, editor